Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Osteoporosis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 65 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | June 2014 |
| End Date: | May 2016 |
This is a pilot study evaluating the recruitment strategies for sites and patients, data
collection instruments, follow-up procedures, administrative processes, and the proposed
management strategy for the future large scale national trial. This pilot study is 6 months
in length.
collection instruments, follow-up procedures, administrative processes, and the proposed
management strategy for the future large scale national trial. This pilot study is 6 months
in length.
Inclusion Criteria:
1.Females 65+
2.3+ years of alendronate (Fosamax/Binosto) use
3. Valid social security number
Exclusion Criteria:
1. History of any other metabolic bone condition, such as Paget Disease of Bone
2. Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.
3. Has significant underlying illness that would be expected to prevent completion of
the study (e.g., life-threatening disease likely to limit survival to less than 3
years)?
4. HIV positive
5. Involved in a conflicting (investigational drug) clinical trial
We found this trial at
1
site
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
